European Surveillance of Immunoglobulin Safety—Results of Initial Survey of 1243 Patients with Primary Immunodeficiencies in 16 Countries

A European multicenter study was conducted to obtain information on the current practices of immunoglobulin administration, the policies in use for the surveillance of the risk of hepatitis C virus (HCV) transmission, and the natural history of HCV infection in patients with hypogammaglobulinemia. D...

Full description

Saved in:
Bibliographic Details
Published in:Clinical immunology (Orlando, Fla.) Fla.), 2002-09, Vol.104 (3), p.231-236
Main Authors: Quinti, Isabella, Pierdominici, Marina, Marziali, Marco, Giovannetti, Antonello, Donnanno, Simona, Chapel, Helen, Bjorkander, Janne, Aiuti, Fernando
Format: Article
Language:English
Subjects:
Adolescent
Adult
Agammaglobulinemia - genetics
Agammaglobulinemia - therapy
Aged
Aged, 80 and over
Biological and medical sciences
Common Variable Immunodeficiency - therapy
CVID
Female
HCV
hepatitis
Hepatitis C - diagnosis
Hepatitis C - etiology
Hepatitis C - transmission
Humans
Immunodeficiencies
Immunodeficiencies. Immunoglobulinopathies
immunoglobulins
Immunoglobulins - administration & dosage
Immunoglobulins - adverse effects
Immunoglobulins, Intravenous - administration & dosage
Immunologic Deficiency Syndromes - therapy
Immunomodulators
Immunopathology
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
RNA, Viral - analysis
safety
transmission
XLA
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A European multicenter study was conducted to obtain information on the current practices of immunoglobulin administration, the policies in use for the surveillance of the risk of hepatitis C virus (HCV) transmission, and the natural history of HCV infection in patients with hypogammaglobulinemia. Data from 1243 patients with primary immunodeficiencies in 16 countries demonstrated that 90% of patients with antibody deficiencies receive intravenous immunoglobulins in an inpatient setting, and 7% of patients are treated with subcutaneous immunoglobulins, mainly at home. Wide variations have been reported regarding the frequency and the type of tests monitored for the surveillance on the risk of viral hepatitis transmission. Only 60% of patients have been tested at least once for HCV RNA detection. Data from 71 HCV-infected patients demonstrated a rapid progression of HCV infection, with end-stage liver disease, in about 40% of patients. Ten percent of patients spontaneously cleared the virus, and about 30% are asymptomatic. Patients with CVID have a worse prognosis than patients with XLA.
ISSN:1521-6616
1521-7035
DOI:10.1006/clim.2002.5239